Patents Examined by Regina M. DeBerry
  • Patent number: 11117976
    Abstract: The present application discloses a previously unknown function of CD24 expressed on a subset of dendritic cells. The invention encompasses regulating CD24 on these cells to regulate erythropoiesis, induce EPO production and levels, increase RBC levels, and to treat, for example, stress-mediated erythropoiesis. The compositions and methods of the invention are useful, for example, in treating anemia.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: September 14, 2021
    Assignee: University of Virginia Patent Foundation
    Inventors: Thomas J. Braciale, Taeg S. Kim
  • Patent number: 11078270
    Abstract: The invention relates to negative functional modulators of erythropoietin (EPO) for use in the treatment of cancers, in the therapy of autoimmune -based and non-autoimmune based chronic inflammatory diseases, and in the treatment of patients under-going organ or tissue transplant, or for the treatment of hemophilic arthropathy, hemophilia A and B, von Willebrand disease, angiodysplasia, proliferative disorders and neurological diseases characterized in their pathogenesis by primary neuroinflammation and/or neuroinflammation secondary to other causes. Such modulators are anti-EPO antibodies and their derivatives: anti-EPO receptor antibodies (EPOR), antisense oligonucleotides, decoy DNA, decoy RNA, ribozyme, antagomir, shRNA, LNA and/or siRNAs that inhibit the expression of the gene encoding EPO or EPOR.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: August 3, 2021
    Assignee: ANDREMACON S.R.L.
    Inventors: Giovanni Marfia, Stefania Elena Navone, Giuseppe Scalvini, Laura Riboni, Rolando Campanella
  • Patent number: 11066658
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: July 20, 2021
    Assignee: OPKO BIOLOGICS LTD.
    Inventors: Udi Eyal Fima, Gili Hart
  • Patent number: 11020450
    Abstract: The present invention relates to a medical use of Cellular Repressor of E1A-stimulated Genes (CREG), in particular to a use of CREG protein or active fragment thereof in manufacture of a medicament for preventing and/or treating myocardial infarction, a use in manufacture of a medicament for preventing and/or treating ventricular remodeling after myocardial infarction and heart failure after myocardial infarction, a use in manufacture of a medicament for prevention and/or treatment of myocardial ischemia-reperfusion injury, a use in manufacture of a medicament for prevention and/or treatment of salt-sensitive hypertensive myocardial fibrosis.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: June 1, 2021
    Assignee: GENERAL HOSPITAL OF CHINESE PLA NORTHERN THEATER COMMAND
    Inventors: Yaling Han, Chenghui Yan, Dan Liu, Xiaoxiang Tian, Yang Li, Xiaolin Zhang, Haixu Song, Meili Liu
  • Patent number: 11008389
    Abstract: Uses of a dual V region antibody-like protein or a fragment of a dual V region antibody-like region.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 18, 2021
    Assignee: SANOFI
    Inventors: Florent C. Bender, Danxi Li, Anne Minnich, Amirtha Naadimuthu, Ercole Rao, Brian N. Swanson, Lei Tang, Haixin Yu, Otmane Boussif, Sophie Carayon
  • Patent number: 10954282
    Abstract: This invention provides nucleic acid molecules encoding the N-terminal 158 amino acids of secreted human Fibroblast Growth Factor Binding Protein 3 (NBP158), pharmaceutical compositions comprising NBP158 polypeptide, and methods for treating metabolic disorders and conditions using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: March 23, 2021
    Inventor: Wentao Zhang
  • Patent number: 10858409
    Abstract: The present invention provides an isolated or recombinant protein consisting of the amino acid sequence according to SEQ ID NO: 3 or SEQ ID: NO: 4 and its use in the prevention or treatment of an inflammatory condition.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: December 8, 2020
    Assignee: IMMUNE REGULATION LIMITED
    Inventors: Valerie Mary Corrigall, Gabriel Stavros Panayi
  • Patent number: 10859579
    Abstract: The present invention relates to methods for detecting, diagnosing and/or treating ulcerative interstitial cystitis (UIC) by detecting in a urine sample from a patient the levels of each of the proteins IL-6, IL-8 and GRO [also known as CXCL 1 (chemokine C-X-C motif ligand 1]. In some embodiments, the method also includes diagnosing the patient with UIC when each of the proteins IL-6, IL-8 and GRO in the urine sample is at a different level than a statistically validated threshold for the respective proteins. In some embodiments a companion diagnostic, e.g., a cystoscopy, is used in conjunction with the protein biomarker diagnostic. In some embodiments, once UIC is diagnosed, the patient is treated for the UIC.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: December 8, 2020
    Assignee: WILLIAM BEAUMONT HOSPITAL
    Inventors: Michael B. Chancellor, Laura Lamb, Joseph J. Janicki
  • Patent number: 10829549
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: November 10, 2020
    Assignee: Jannsen Biotech, Inc.
    Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • Patent number: 10829531
    Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sideroblastic anemias and myelodysplastic syndromes or one or more complications associated sideroblastic anemias and myelodysplastic syndromes.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: November 10, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Kenneth M. Attie, Christopher Robert Rovaldi
  • Patent number: 10792338
    Abstract: A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: October 6, 2020
    Assignee: Remedor Biomed Ltd.
    Inventor: Saher Hamed
  • Patent number: 10774132
    Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: September 15, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITTUE
    Inventors: Vaughn Smider, Omar A. Bazirgan, Hongyuan Helen Mao, Peter Schultz, Feng Wang, Yong Zhang
  • Patent number: 10774153
    Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: September 15, 2020
    Assignees: UNIVERSITE D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Marcel Blot-Chabaud, Karim Harhouri, Nathalie Bardin, Benjamin Guillet, Francoise Dignat-George
  • Patent number: 10759871
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 1, 2020
    Assignee: SANOFI
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • Patent number: 10745455
    Abstract: Fusion polypeptides capable of binding endothelin-1 to form a non-functional complex are provided, including amino acid sequences of the fusion polypeptides. The fusion polypeptides will be linked to the Fe portion of human IgG I to form dimers that will function as endothelin-1 antagonists (endothelin-1 sponge).
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: August 18, 2020
    Inventor: Arjun Jain
  • Patent number: 10723775
    Abstract: The present invention relates to a method for purifying darbepoetin alfa by selectively separating only a structural isoform having a high content of sialic acid from a mixture of structural isoforms of darbepoetin alfa having various contents of sialic acid. Since the method of the present invention is a novel method for purifying darbepoetin alfa which can be conveniently and simply produced, it is possible to remarkably increase productivity due to process efficiency improvement, as well as to yield high purity darbepoetin alfa when mass-producing darbepoetin alfa according to the present invention.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: July 28, 2020
    Assignee: CJ Healthcare Corporation
    Inventors: Yoon Jung Lee, Kyung Hwa Kim, Yoo Hee Yang, Jung Min Yoo, Se Jun Kim, Ji Hyun Moon, Hoo Keun Oh, Dong Eok Lee, Won Jeong Lee, Jung Rok Lee, Chung Min Lee, Eun Young Choi, Gyong Sik Ha
  • Patent number: 10711052
    Abstract: The present invention discloses a method for treating wounds and for accelerating the healing of wounds by administering an effective amount of a pharmaceutical composition containing type VII collagen protein, mini-C7 protein, variants thereof or any combinations thereof. The pharmaceutical composition may be administered through a variety of routes including intravenous injection, topical application, or oral ingestion. The method may further include administering a genetically modified fibroblast capable of expressing type VII collagen protein, mini-C7 protein, variants thereof or small growth factors to achieve synergistic healing effect.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: July 14, 2020
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Mei Chen, David Woodley
  • Patent number: 10702583
    Abstract: The present invention provides methods and compositions for expanding T regulatory cells ex vivo or in vivo using one or more SAP agonists. The methods and compositions are useful in the treatment of autoimmune diseases and in preventing foreign graft rejection.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: July 7, 2020
    Assignee: Promedior, Inc.
    Inventor: Lynne Anne Murray
  • Patent number: 10668154
    Abstract: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: June 2, 2020
    Assignee: Amgen Inc.
    Inventors: Tiansheng Li, Christopher James Sloey
  • Patent number: 10640758
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: May 5, 2020
    Assignee: OPKO Biologics Ltd.
    Inventors: Udi Eyal Fima, Gili Hart